Posted by Michael Wonder on 15 Aug 2024
Kiromic BioPharma’s Deltacel receives FDA fast track designation
14 August 2024 - Kiromic BioPharma announces that the US FDA has granted fast track designation to Deltacel (KB-GDT-01), the Company’s allogeneic, off the shelf, gamma delta T-cell therapy.
The designation was awarded for KB-GDT-01 in combination with low-dose radiation therapy for the treatment of patients with metastatic non-small cell lung cancer who have progressed on at least two lines of standard of care therapy including platinum-based chemotherapy, immune checkpoint inhibitors and targeted therapy to improve progression-free survival and overall survival.
